Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
104-week extension trial of glepaglutide in adults with short bowel syndrome completing EASE SBS 2
2020-005502-25Phase 3Active
- Sponsor
- Zealand Pharma
- Start
- Mar 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Started Mar 2021; status: active.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2020-005502-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005502-25.